Projecting future drug expenditures - 1998

American Journal of Health-System Pharmacy

Volumn 55, Issue 2, 1998, Pages 127-136

  Mehl, Bernard ^a   Santell, John P ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b AMERICAN SOCIETY OF HEALTH SYSTEM PHARMACISTS   (United States)

Author keywords

Costs; Drug distribution; Economics; Formularies; Industry, pharmaceutical; Mergers; Pharmacoeconomics; Pharmacy, institutional; Purchasing

Indexed keywords

ANAGRELIDE; ARDEPARIN; BROMFENAC; DELAVIRDINE; DOFETILIDE; EMEDASTINE; EPROSARTAN; FENOLDOPAM MESILATE; FLUTICASONE PROPIONATE; LEPIRUDIN; LETROZOLE; LIAROZOLE; MIBEFRADIL; NERVE GROWTH FACTOR; NEW DRUG; PRAMIPEXOLE; QUETIAPINE; RALOXIFENE; RALTITREXED; RASAGILINE; RECOMBINANT STEM CELL FACTOR; STEM CELL FACTOR; TAMSULOSIN; THALIDOMIDE; TIAGABINE; TILUDRONIC ACID; TIRILAZAD; TOLCAPONE; TOREMIFENE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG INFORMATION; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; PUBLICATION; REVIEW;

EID: 0031910689     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.2.127     Document Type: Review

References (38)

1. Bullish new products and macro events powering earnings flow. New York: Gruntal Investment Research; 1997 Jan 21:1.
2. FDA clears 53 NMEs in 1996. FDC Rep. 1997; 59(Jan 6):19-24.
3. Center for Drug Evaluation and Research. Food and drug approvals list. Food and Drug Administration; 1997.
4. Prices of drugs increase faster than inflation. N Y Times. 1997; Feb 13:B-4.
5. Johannes L. Some HMOs now put doctors on a budget for prescription drugs. Wall Str J. 1997; May 22:A-1, A-6.
6. Mergers, acquisitions set a record despite 4th quarter slowdown. AHA News. 1997; Jan 27:5.
7. The urge to merge is contagious. Inst Inv. 1996; Dec: 20 Sponsored section.
8. CPI: medical care up slightly. AHA News. 1997; Feb 24:4.
9. Nine states to introduce managed care legislation. AHA News. 1997; Jan 20:5.
10. How do you tame a wild U.S. program? N Y Times. 1997; Mar 6:1.
11. Kilborn PT. Doctors organize to fight corporate intrusion. N Y Times. 1997; Jul 1:A12.
12. Mehl B, Santell JP. Projecting future drug expenditures -1997. Am J Health-Syst Pharm. 1997; 54:153-61.
13. Santell JP. Projecting future drug expenditures - 1996. Am J Health-Syst Pharm. 1996; 53:139-50.
14. Santell JP. Projecting future drug expenditures - 1995. Am J Health-Syst Pharm. 1995; 52:151-63.
15. Santell JP. Projecting future drug expenditures - 1994. Am J Hosp Pharm. 1994; 51:177-87.
16. Santell JP. Projecting future drug expenditures - 1993. Am J Hosp Pharm. 1993; 50:71-7.
17. Ensor PA. Projecting future drug expenditures - 1992. Am J Hosp Pharm. 1992; 49:140-5.
18. Vaughn RA, Yannitelli PF. Price index provides model for 22 pharmaceutical categories. Hosp Purch Manage. 1978; 4:13-6.
19. Vaughn RA. This hospital service forecasts inflation for its fiscal health. Manage Account. 1978; 4(Dec):44-7.
20. Mehl B. Indicators to control drug costs in hospitals. Am J Hosp Pharm. 1984; 41:667-75.
21. Mehl B. Benchmarking price indexes: caution. Hosp Pharm. 1997; 32:768.
22. Myshko D. The best pipelines. R&D Directions. 1997; 3(1):16-45.
23. With patents expiring on big prescriptions, drug industry quakes, Wall Str J. 1997; Aug 12:A-1,A-6.
24. Precious time. R&D Directions. 1997; 3(4):30-1.
25. Horn SD, Sharkey PD, Tracy DM et al. Intended and unintended consequences of HMO cost-containment strategies: results from Managed Care Outcomes Project. Am J Manag Care. 1996; 2:253-64.
26. Curtiss FR. Drug formularies provide a path to best care. Am J Health-Syst Pharm. 1996; 53:2201-3.
27. Kravitz RL, Romano PS. Managed care cost containment and the law of unintended consequences. Am J Manag Care. 1996; 2:232-4. Editorial.
28. Horn SD. Unintended consequences of drug formularies. Am J Health-Syst Pharm. 1996; 53:2204-6.
29. Freudenheim M. Not quite what the doctor ordered. N Y Times. 1996; Oct 8:D-1,D-6.
30. Kennedy/Dingell anti-formulary rhetoric accompanies managed care bill. FDC Rep. 1997; 59(Mar 3):T5,G5.
31. Therapeutic switches resulting in adverse events. Weekly Pharm Rep. 1997; 46(Mar 10):2.
32. Ukens C. Sub-attack. Drug Top. 1997; 141(5):21.
33. Jaklevic MC. Prescribed cutback. Mod Healthc. 1997; 27(9):34.
34. Hospital groups forming partnerships with PBMs. Hosp Pharm Rep. 1997; 11(2):70.
35. Eichenwald K. Columbia/HCA halting merger and capital plans. N Y Times. 1997; Aug 29:D-1,D-2.
36. Carroll NV. Changes in channels of distribution. Hosp Pharm Rep. 1997; 11(2):48,55.
37. Freudenheim M. Creating no. 1 drug wholesaler, Cardinal to buy Bergen Brunswig. N Y Times. 1997; Aug 26:D-1,D-2.
38. Vecchione A. A merger with Owen increases Cardinal's presence in automation. Hosp Pharm Rep. 1997; 11(1):56.